\begin{table}[ht]
\resizebox{\textwidth}{!}{%
\begin{tabular}{|c|c|c|c|}
\hline
Drug\_name             & Clinical phase  & Mechanism of Action                                       & Number of targeted proteins \\ \hline
fenebrutinib           & Phase 2         & Bruton's tyrosine kinase (BTK) inhibitor                  & 80                          \\ \hline
PF-05190457            & Phase 2         & growth hormone secretagogue receptor inverse agonist      & 50                          \\ \hline
MK-5046                & Preclinical     & bombesin receptor agonist                                 & 38                          \\ \hline
CCT137690              & Preclinical     & Aurora kinase inhibitor                                   & 36                          \\ \hline
AI-10-49               & Preclinical     & core binding factor inhibitor                             & 31                          \\ \hline
abemaciclib            & Launched        & CDK inhibitor                                             & 26                          \\ \hline
CFI-402257             & Phase 1/Phase 2 & dual specificity protein kinase inhibitor                 & 20                          \\ \hline
NMS-P715               & Preclinical     & protein kinase inhibitor                                  & 14                          \\ \hline
NMS-1286937            & Phase 2         & PLK inhibitor                                             & 11                          \\ \hline
elbasvir               & Launched        & HCV inhibitor                                             & 8                           \\ \hline
cilofexor              & Phase 3         & FXR agonist                                               & 7                           \\ \hline
ABBV-744               & Phase 1         & bromodomain inhibitor                                     & 7                           \\ \hline
tropifexor             & Phase 2         & FXR agonist                                               & 7                           \\ \hline
CDK9-IN-6              & Preclinical     & CDK inhibitor                                             & 6                           \\ \hline
adapalene              & Launched        & retinoid receptor agonist                                 & 4                           \\ \hline
Q-203                  & Phase 2         & ATP synthase inhibitor                                    & 4                           \\ \hline
PLX8394                & Phase 1/Phase 2 & serine/threonine kinase inhibitor                         & 4                           \\ \hline
ABT-702                & Preclinical     & adenosine kinase inhibitor                                & 4                           \\ \hline
NVP-BSK805             & Preclinical     & JAK inhibitor                                             & 3                           \\ \hline
OTS167                 & Phase 1/Phase 2 & maternal embryonic leucine zipper kinase inhibitor        & 3                           \\ \hline
CHIR-99021             & Preclinical     & glycogen synthase kinase inhibitor                        & 3                           \\ \hline
DBPR-211               & Preclinical     & cannabinoid receptor antagonist                           & 2                           \\ \hline
A-887826               & Preclinical     & sodium channel blocker                                    & 2                           \\ \hline
integrin-antagonist-1  & Phase 1         & integrin antagonist                                       & 2                           \\ \hline
piperaquine-phosphate  & Launched        & antimalarial agent                                        & 2                           \\ \hline
cenerimod              & Phase 2         & sphingosine 1-phosphate receptor modulator                & 1                           \\ \hline
peposertib             & Phase 1/Phase 2 & DNA dependent protein kinase inhibitor                    & 1                           \\ \hline
tezacaftor             & Launched        & CFTR channel agonist                                      & 1                           \\ \hline
cot-inhibitor-2        & Preclinical     & MAPK-interacting kinase inhibitor                         & 1                           \\ \hline
itacitinib             & Phase 3         & JAK inhibitor                                             & 1                           \\ \hline
10-hydroxycamptothecin & Preclinical     & topoisomerase inhibitor                                   & 1                           \\ \hline
alectinib              & Launched        & ALK tyrosine kinase receptor inhibitor                    & 1                           \\ \hline
adarotene              & Phase 1         & retinoid receptor agonist                                 & 1                           \\ \hline
acalabrutinib          & Launched        & Bruton's tyrosine kinase (BTK) inhibitor                  & 1                           \\ \hline
XL041                  & Preclinical     & LXR agonist                                               & 1                           \\ \hline
WAY-207024             & Preclinical     & gonadotropin releasing factor hormone receptor antagonist & 1                           \\ \hline
MK-5108                & Phase 1         & Aurora kinase inhibitor                                   & 1                           \\ \hline
CGM097                 & Phase 1         & MDM inhibitor                                             & 1                           \\ \hline
CD-437                 & Preclinical     & retinoid receptor agonist                                 & 1                           \\ \hline
AMG-925                & Phase 1         & CDK inhibitor|FLT3 inhibitor                              & 1                           \\ \hline
ACT-132577             & Launched        & endothelin receptor antagonist                            & 1                           \\ \hline
ziritaxestat           & Phase 3         & autotaxin inhibitor                                       & 1                           \\ \hline
\end{tabular}%
}
\caption{Chemicals interacted with undruggable human proteins excluding Tbio} 
    \label{tab:UndrugnoTbiochemicals}
\end{table}
Drug_name Clinical phase Mechanism of Action Number of targeted proteins
fenebrutinib Phase 2 Bruton’s tyrosine kinase (BTK) inhibitor 80
PF-05190457 Phase 2 growth hormone secretagogue receptor inverse agonist 50
MK-5046 Preclinical bombesin receptor agonist 38
CCT137690 Preclinical Aurora kinase inhibitor 36
AI-10-49 Preclinical core binding factor inhibitor 31
abemaciclib Launched CDK inhibitor 26
CFI-402257 Phase 1/Phase 2 dual specificity protein kinase inhibitor 20
NMS-P715 Preclinical protein kinase inhibitor 14
NMS-1286937 Phase 2 PLK inhibitor 11
elbasvir Launched HCV inhibitor 8
cilofexor Phase 3 FXR agonist 7
ABBV-744 Phase 1 bromodomain inhibitor 7
tropifexor Phase 2 FXR agonist 7
CDK9-IN-6 Preclinical CDK inhibitor 6
adapalene Launched retinoid receptor agonist 4
Q-203 Phase 2 ATP synthase inhibitor 4
PLX8394 Phase 1/Phase 2 serine/threonine kinase inhibitor 4
ABT-702 Preclinical adenosine kinase inhibitor 4
NVP-BSK805 Preclinical JAK inhibitor 3
OTS167 Phase 1/Phase 2 maternal embryonic leucine zipper kinase inhibitor 3
CHIR-99021 Preclinical glycogen synthase kinase inhibitor 3
DBPR-211 Preclinical cannabinoid receptor antagonist 2
A-887826 Preclinical sodium channel blocker 2
integrin-antagonist-1 Phase 1 integrin antagonist 2
piperaquine-phosphate Launched antimalarial agent 2
cenerimod Phase 2 sphingosine 1-phosphate receptor modulator 1
peposertib Phase 1/Phase 2 DNA dependent protein kinase inhibitor 1
tezacaftor Launched CFTR channel agonist 1
cot-inhibitor-2 Preclinical MAPK-interacting kinase inhibitor 1
itacitinib Phase 3 JAK inhibitor 1
10-hydroxycamptothecin Preclinical topoisomerase inhibitor 1
alectinib Launched ALK tyrosine kinase receptor inhibitor 1
adarotene Phase 1 retinoid receptor agonist 1
acalabrutinib Launched Bruton’s tyrosine kinase (BTK) inhibitor 1
XL041 Preclinical LXR agonist 1
WAY-207024 Preclinical gonadotropin releasing factor hormone receptor antagonist 1
MK-5108 Phase 1 Aurora kinase inhibitor 1
CGM097 Phase 1 MDM inhibitor 1
CD-437 Preclinical retinoid receptor agonist 1
AMG-925 Phase 1 CDK inhibitor|FLT3 inhibitor 1
ACT-132577 Launched endothelin receptor antagonist 1
ziritaxestat Phase 3 autotaxin inhibitor 1